Unión Europea - maltés - EMA (European Medicines Agency)

sanquin plasma products b.v. - fattur tal-koagulazzjoni uman ix - hemofilja b - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja b (defiċjenza konġenitali tal-fattur ix).

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina lispro - diabetes mellitus - drogi użati fid-dijabete - għat-trattament ta 'adulti u tfal b'dijabete mellitus li jeħtieġu l-insulina għall-manteniment ta' omeostasi normali tal-glukożju. insulin lispro sanofi huwa indikat ukoll għall-istabbilizzazzjoni inizjali tad-dijabete mellitus.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi b.v. - eliglustat - mard gaucher - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - cerdelga huwa indikat għall-fit-tul it-trattament tal-pazjenti adulti ma gaucher il-marda tat-tip 1 (gd1), li huma metabolisers fqir cyp2d6 (pms), metabolisers intermedjarji (ims) jew metabolisers estensiva (ems).

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - irbesartan, hydrochlorothiazide - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. din il-kombinazzjoni tad-doża fissa hija indikata f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat fuq irbesartan jew hydrochlorothiazide waħdu.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - irbesartan, hydrochlorothiazide - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. din il-kombinazzjoni ta 'doża fissa hija indikata f'pazjenti adulti li l-pressjoni tad-demm tagħhom mhix ikkontrollata b'mod adegwat fuq irbesartan jew hydrochlorothiazide waħdu.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - majloma multipla - aġenti antineoplastiċi - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, tip 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obeżità - preparazzjonijiet ta 'kontra l-ossessjoni, esklużi prodotti tad-dieta - bħala żieda mad-dieta u l-eżerċizzju fil-kura tal-pazjenti bi ħxuna żejda (bmi 30 kg/m2), jew ta'pazjenti b'piż eċċessiv (bmi 27 kg/m2) bl-riskju assoċjat fattur(i), bħalma huma dijabete tip 2 jew dislipidemija (ara sezzjoni 5.

Unión Europea - maltés - EMA (European Medicines Agency)

sanofi pasteur s.a. - qasma-virus tal-influwenza, inattivat, li fih antiġen*:/california/7/2009 (h1n1)v like strain (x-179a)*propagati fil-bajd. - influenza, human; immunization; disease outbreaks - vaċċini - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. vaċċin għal influwenza pandemika għandu jintuża skont il-gwida uffiċjali.